ICER's Growing Impact On Drug Pricing And Reimbursement

In the U.S., ICER is gaining traction, in ways perhaps unimaginable several years ago. For many years it was thought that the U.S. would be immune to cost-effectiveness thresholds. It was common to hear the refrain: "We don't do rationing here, at least not explicitly."